Clinical Trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Trial Details
NCT Number NCT07510802
Lead Sponsor Beijing Biotech
Conditions Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Enrollment 60 participants
Start Date 2026-02-02
Primary Completion 2027-03-14 (estimated)
Study Completion 2028-04-17 (estimated)
Updated on ClinicalTrials.gov 2026-04-06